Collecting Data and Blood Samples From Prostate Cancer Patients Receiving Lutetium Treatment
Collects blood samples and treatment data from adults with metastatic prostate cancer receiving Lu-PSMA therapy.
Plain-language title generated from the registry record
Registry title: Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics
Key facts
- Where
- Rotterdam, NetherlandsSee the site
Where in Netherlands
- Erasmus MCRotterdam, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Erasmus Medical Center
- Trial code
- NCT06260410
- Record updated
- 22 April 2024
- Original description
This prospective study aims to collect data and blood biomarkers from patients undergoing Lu-PSMA therapy at the Erasmus MC. In doing so, it will provide real-world efficacy and safety data on the drug, gather dosimetry data and explore putative biomarkers to identify patients who most benefit from Lu-PSMA treatment.Read full original descriptionShow less
Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics
This prospective study aims to collect data and blood biomarkers from patients undergoing Lu-PSMA therapy at the Erasmus MC. In doing so, it will provide real-world efficacy and safety data on the drug, gather dosimetry data and explore putative biomarkers to identify patients who most benefit from Lu-PSMA treatment.
Inclusion: Participants should be at least 18 years old; Participants should be able to understand the written information and be able to provide informed consent; Participants are planned to start treatment with Lu-PSMA as a part of regular clinical care.
Exclusion: None applicable.